Results 211 to 220 of about 5,673,125 (350)
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study [PDF]
Eiji Shinozaki +24 more
openalex +1 more source
This study has characterized a functionally distinct macrophage subset, termed CCL5hi macrophages, and elucidated the underlying mechanisms of a regulatory feedback loop that interconnects IFN‐γ, CCL5hi macrophages, and CD8+ T cells within the TME of ESCC undergoing immunochemotherapy.
Yuanzhen Ma +10 more
wiley +1 more source
Biomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers. [PDF]
Zamanian MY +5 more
europepmc +1 more source
Figure S5 from Residential Segregation and Colorectal Cancer Screening in the United States, 2010 to 2018 [PDF]
Eduardo J. Santiago‐Rodríguez +5 more
openalex +1 more source
FBXO44 promotes colorectal cancer progression by targeting FOXP1 for ubiquitin‐mediated degradation. This study reveals a phosphorylation‐dependent mechanism involving AURKA and highlights the FBXO44/FOXP1/Cyclin E2 axis as a potential therapeutic target in colorectal cancer.
Hongxu Nie +10 more
wiley +1 more source
Prkci acts a pro-proliferation factor in colorectal cancer. [PDF]
Li P, Liu G, Zhang W, Li T.
europepmc +1 more source
Steroid receptor coactivator‐1 (SRC‐1) reprograms tumor‐associated macrophages (TAMs) via signal transducer and activator of transcription 1(STAT1)‐mediated matrix metallopeptidase 12 (MMP12) transcription to drive perineural invasion (PNI) in pancreatic cancer.
Ke Cheng +9 more
wiley +1 more source
In situ forming hydrogels for colorectal cancer therapy. [PDF]
Yao Q +5 more
europepmc +1 more source

